Split core technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgE

dc.contributor.author	Baltabekova, A. Zh.
dc.contributor.author	Shagyrova, Zh. S.
dc.contributor.author	Voykov, M.
dc.contributor.author	Ramanculov, E. M.
dc.contributor.author	Shustov, A. V.
dc.date.accessioned	2015-10-22T11:53:03Z
dc.date.available	2015-10-22T11:53:03Z
dc.date.issued	2014
dc.identifier.uri	http://nur.nu.edu.kz/handle/123456789/424
dc.description.abstract	Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces antibodies against a receptor-contacting epitope on human IgE molecule.	ru_RU
dc.language.iso	en	ru_RU
dc.publisher	Nazarbayev University	ru_RU
dc.subject	immunoglobulin E	ru_RU
dc.subject	human IgE	ru_RU
dc.subject	immunodominant region	ru_RU
dc.subject	split core technology	ru_RU
dc.title	Split core technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgE	ru_RU
dc.type	Abstract	ru_RU